Meta-analysis indicates low testosterone levels are associated with increased cancer mortality risk — Evidence Review
Published in The Lancet Healthy Longevity, by researchers from The University of Western Australia
Researched by
— the AI search engine for science
Table of Contents
A large study has found that men with very low testosterone levels are at greater long-term risk of cancer death, though this association does not apply to prostate cancer. Most related studies agree that low testosterone is linked to increased overall mortality, but the relationship with cancer risk—especially prostate cancer—remains complex, as discussed in the original study source.
- Multiple cohort studies have consistently found that low testosterone is associated with higher all-cause and cancer-specific mortality in men, supporting the new study’s findings that testosterone may serve as a health biomarker rather than a direct cause of cancer 6 7 8 10.
- Regarding prostate cancer, evidence remains mixed: some studies suggest low testosterone is linked to lower overall prostate cancer risk, while others note associations only with specific subtypes or grades, and most do not find that higher testosterone increases prostate cancer incidence 1 2 4 5.
- The new study's finding that low testosterone does not predict prostate cancer aligns with recent clinical trials showing that testosterone replacement therapy does not significantly affect prostate cancer risk in carefully screened men 3 5.
Study Overview and Key Findings
Understanding the potential role of testosterone as a biomarker for cancer risk could help identify men who may benefit from closer health monitoring. This large-scale international meta-analysis stands out for its use of longitudinal hormone measurements from blood samples collected years before cancer diagnosis, allowing for robust assessment of long-term risks. Importantly, the study distinguishes between overall cancer risk and prostate cancer, offering greater clarity on a topic historically marked by uncertainty.
| Property | Value |
|---|---|
| Study Year | 2026 |
| Organization | The University of Western Australia |
| Journal Name | The Lancet Healthy Longevity |
| Authors | Ross J Marriott, Kevin Murray, Leen Antonio, Robert J Adams, Christie M Ballantyne, Douglas C Bauer, Shalender Bhasin, Mary L Biggs, Peggy M Cawthon, David J Couper, Adrian S Dobs, Leon Flicker, Nele Friedrich, David J Handelsman, Graeme J Hankey, Anke Hannemann, Calvin H Hirsch, Benjumin Hsu, Sean A Martin, Alvin M Matsumoto, Bu B Yeap |
| Population | Men with varying testosterone levels |
| Sample Size | n=26,000 |
| Methods | Meta-Analysis |
| Outcome | Cancer diagnosis and mortality related to testosterone levels |
| Results | Men with low testosterone had an 18% higher risk of dying from cancer. |
Literature Review: Related Studies
To situate these findings within the broader body of scientific evidence, we searched the Consensus database, which includes over 200 million research papers. The following queries were used to identify relevant studies:
| Topic | Key Findings |
|---|---|
| Is low testosterone a marker for higher overall mortality and cancer risk in men? | - Low testosterone is associated with increased risk of all-cause mortality, cardiovascular mortality, and cancer mortality in multiple cohort studies 6 7 8 10. - Testosterone treatment in men with low testosterone may be linked to lower mortality, but large randomized trials are lacking 9. |
| How does testosterone relate specifically to prostate cancer risk and progression? | - Low circulating free testosterone is associated with reduced overall prostate cancer risk, but may be linked to more aggressive disease if cancer does develop 1 4. - No clear evidence that higher endogenous or replacement testosterone increases prostate cancer incidence; some reviews suggest the relationship is indirect or confounded by other factors 2 3 5. |
| What is the safety profile of testosterone replacement therapy (TRT) regarding cancer? | - Large randomized controlled trials show no significant increase in prostate cancer risk or adverse prostate events with TRT in hypogonadal men 3 5. - Some reviews recommend careful monitoring, but current evidence suggests TRT may be safe for select patients, including those with a history of prostate cancer 5. |
| Can blood-based tests provide early detection or warning signs for cancer risk? | - Multi-cancer early detection (MCED) tests and circulating DNA methylation assays can identify cancer years before clinical diagnosis with high specificity, but their clinical utility and integration with hormone biomarkers require further research 11 12 13 14 15. - PanSeer and other tests have shown high sensitivity in detecting cancer in asymptomatic individuals up to four years before conventional diagnosis 13. |
Is low testosterone a marker for higher overall mortality and cancer risk in men?
Consistent with the current study, multiple large cohort studies have found that men with low circulating testosterone are at greater risk of all-cause mortality, including deaths from cancer and cardiovascular disease. These studies suggest that testosterone may be a general biomarker of poorer health or increased vulnerability, rather than a direct cause of cancer.
- Low testosterone predicts increased cancer and cardiovascular mortality in several population-based and veteran cohorts 6 7 8 10.
- The increased mortality risk persists after adjustment for age, comorbidities, and lifestyle factors, indicating an independent association 6 8 10.
- Testosterone treatment in men with low testosterone has been associated with reduced mortality in observational studies, though randomized trials are needed for confirmation 9.
- These findings support the interpretation that low testosterone is a marker of overall health status, echoing the conclusions of the new study 6 7 8 10.
How does testosterone relate specifically to prostate cancer risk and progression?
The association between testosterone and prostate cancer has been debated. Some studies report that low free testosterone is linked to a lower risk of developing prostate cancer, while the risk of aggressive or high-grade disease may be higher among those with very low testosterone. The new study’s finding—no association between testosterone and prostate cancer risk—aligns with the broader literature.
- A large meta-analysis found that men in the lowest tenth of free testosterone had a reduced risk of overall prostate cancer, but potentially higher risk of aggressive subtypes 1 4.
- Reviews and clinical data show no consistent link between higher testosterone (either natural or from TRT) and increased prostate cancer risk 2 3 5.
- The relationship may be influenced by factors such as detection bias, age, comorbidities, and the biology of advanced prostate cancers 2 4.
- The nuanced findings of the new study fit within this complex and evolving evidence base 1 2 3 4 5.
What is the safety profile of testosterone replacement therapy (TRT) regarding cancer?
Recent large randomized controlled trials and systematic reviews indicate that TRT, when prescribed to appropriately screened men, does not significantly raise the risk of prostate cancer or related adverse events. These findings have informed changes in clinical guidelines regarding TRT use.
- A recent RCT found no significant difference in prostate cancer incidence or high-grade prostate cancers between TRT and placebo in hypogonadal men 3.
- Reviews suggest TRT may be safe even for selected men with a history of prostate cancer, provided they are closely monitored 5.
- These data support the current study’s recommendation that men should not begin TRT solely to reduce cancer risk, and should consult with healthcare providers if low testosterone is detected 3 5.
- Ongoing surveillance and individualized risk assessment remain important 5.
Can blood-based tests provide early detection or warning signs for cancer risk?
Advances in multi-cancer early detection (MCED) blood tests have shown promise for identifying cancers—including in asymptomatic individuals—years before conventional diagnosis. However, the integration of hormone biomarkers such as testosterone into these tests has yet to be studied in depth.
- MCED tests based on circulating tumor DNA or methylation patterns can detect multiple cancer types with high specificity and moderate sensitivity, sometimes years before symptoms 11 12 13.
- Studies such as PanSeer have demonstrated cancer detection up to four years ahead of standard diagnostic methods 13.
- Trials like NHS-Galleri and PATHFINDER are evaluating the impact of MCED tests on population-level cancer outcomes 14 15.
- Future research may consider incorporating hormone profiles to enhance risk stratification and early detection strategies 11 12 13 14 15.
Future Research Questions
Although this study advances understanding of testosterone as a potential biomarker for men’s long-term cancer risk, important questions remain. Future research should clarify the mechanisms underlying these associations, explore the role of other hormones and health factors, and evaluate the utility of integrating hormone levels into cancer screening or risk prediction.
| Research Question | Relevance |
|---|---|
| What biological mechanisms link low testosterone to increased cancer mortality in men? | Understanding the biological pathways could clarify whether low testosterone is a causal factor or simply a marker of underlying health problems 6 7 8 10. |
| How do other hormones interact with testosterone to influence cancer risk in men? | The new study found that SHBG and luteinizing hormone were also important for prostate cancer risk, suggesting a complex interplay among multiple hormones 4. |
| Can testosterone levels be used in combination with multi-cancer early detection tests to improve risk prediction? | Integrating hormone biomarkers like testosterone with MCED tests may enhance early cancer detection or risk stratification, but this requires systematic study 11 12 13. |
| Does testosterone replacement therapy reduce cancer risk or mortality in men with low testosterone? | Observational studies suggest potential benefits, but large, long-term randomized trials are needed to determine if TRT can modify cancer risk or outcomes 9. |
| What lifestyle or medical factors most strongly influence testosterone levels and subsequent cancer risk? | Identifying modifiable risk factors could help develop prevention strategies for men at higher risk due to low testosterone 6 7 8 10. |
This article presents a comprehensive, evidence-based summary of the latest research on testosterone and long-term cancer risk in men, highlighting both the findings of a major new study and the broader scientific context.